On 15 September, FDA opened applications for its Expedited IND pilot. It expects to select eight to ten sponsor–qualified research institution pairs, with applications due on 30 October 2026 and selections announced by 18 December. The pilot sits within Operation TrialBlazer, which we wrote about in June. For a small biotech preparing its first human study, there is a near-term decision about whether the programme fits. For the people preparing the submission, the process description brings a drafting decision forward: each component needs a scientific argument that can be read on its own.
FDA asks for each component to be framed as "a discrete, self-contained package, not a partial or fragmentary data drop, with a clear statement of what questions and perspective the sponsor is seeking alignment." Rolling submission therefore brings forward the point at which a discipline's work has to be explained to someone outside the development team. Rolling submission process
The first package establishes a position
Consider a hypothetical programme in which the nonclinical package goes first. Its dose rationale rests on a particular exposure estimate. While the clinical component is being prepared, further analysis changes that estimate.
Someone now has to establish what changed, which conclusions are affected and how the revised rationale relates to the material FDA already received. Updating the protocol alone would leave two accounts of the same decision in the regulatory record. Reusing the earlier wording without checking its assumptions would keep the documents consistent at the expense of accuracy.
This is work a sponsor can plan for. We would keep a short record alongside each component: the source versions used, decisions still provisional, dependencies on other disciplines and the person responsible for resolving each one. That is a way of managing the writing, not an additional pilot requirement.
For the regulatory lead, the staffing decision is whether someone has the time and authority to follow those dependencies across packages. A writer brought in only to finish individual sections may see the discrepancy without being able to resolve it.
What a CRO would be agreeing to
FDA's programme description names contract research organisations among the organisations that could act as qualified research institutions, or QRIs. Its priorities include US-based organisations that commit to support across nonclinical, CMC and clinical disciplines, with clinical trial infrastructure of their own or documented partnerships. External experts may fill gaps in a QRI's in-house capabilities. A small CRO should read those provisions against what it can actually provide before treating the pilot as another service line. Programme criteria
Before a component is submitted, FDA expects the QRI to have determined whether it rests on a scientifically sound rationale and data, and to separate issues that must be fixed to avoid a clinical hold from opportunities to strengthen the application. FDA describes the QRI's endorsement as "a meaningful checkpoint in the pre-IND process." That is a scientific assessment built into the pilot, and a CRO signing up as a QRI is signing up to it.
The commercial agreement deserves equal attention. FDA expects the parties to form their business relationship themselves, and evaluates their applications together as a single package. Application instructions
A scope of work for this arrangement should distinguish preparing a component from assessing its scientific readiness and from reconciling it with the other components. Those activities may involve different people, and they need different allowances for review and revision. It should also say what happens when feedback on the second package requires a change to the first: who assesses the consequence, who commissions any new analysis and who revises the affected text. Leaving that to the next change order turns a scientific question into an administrative one.
The final IND still needs its own review
Most of the pilot takes place before the formal IND. The final, complete IND is what starts the 30-day review window. Before it goes in, FDA expects the sponsor and QRI to carry out a comprehensive evaluation of the whole package with earlier feedback incorporated, and the sponsor remains accountable for its completeness. Components that have not been through the rolling process can go straight into the final submission if routing them through the pilot would delay it. The pilot does not remove the final assembly and review.
For writing teams, we would make that final review answer one question: does the complete package describe the programme as it now stands?
That means checking more than whether all sections are present. A rationale that was sound when first submitted may need qualification after later work. A response to an agency question may have been carried into one document and not another. The reconciliation record should let the final reviewer see those decisions without reconstructing months of correspondence.
A decision before 30 October
For a biotech considering an application, it is worth putting the regulatory lead, scientific leads and proposed QRI in the same room with the component schedule. Ask them when each argument will be ready for external review, and who will keep the later packages aligned with the earlier ones.
The pilot gets questions in front of FDA sooner. A credible writing plan needs to show how the answers will travel through the rest of the IND.